Needham Keeps Buy Rating on Geron (GERN) After Q2 Results

Geron Corporation (NASDAQ:GERN) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 6, Needham reiterated its Buy rating for Geron Corporation (NASDAQ:GERN) with a price target of $5. This decision came after the company reported results for the second quarter of 2025.

The firm highlighted the strong performance of Geron Corporation’s (NASDAQ:GERN) RYTELO  in the second quarter, which surpassed expectations in sales with a notable quarter-over-quarter growth.

Needham Keeps Buy Rating on Geron (GERN) After Q2 Results

A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug.

In the second quarter of 2025, RYTELO net product revenue reached $49 million, rising by 24% compared to the first quarter. The demand for RYTELO also increased by 17% in the second quarter. This compares to just 1% increase in demand in the first quarter. This growth was fueled by new patient starts.

Another positive development was the recent appointment of Harout Semerjian, an experienced commercial hematology and oncology leader, as the new CEO of Geron Corporation (NASDAQ:GERN).

Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharmaceutical company focused on developing therapies for patients with blood cancers.

While we acknowledge the potential of GERN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GERN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.